SB 525334

Key Product Details

Product Description

SB 525334 is a selective inhibitor of transforming growth factor-β receptor I (ALK5, TGF-βRI) (IC₅₀ = 14.3 nM). Inhibits TGF-β1-induced smad2/3 nuclear localization and TGF-βRI-induced mRNA expression in kidney cells. Attenuates bleomycin-induced pulmonary fibrosis.

Licensing Information

Sold with the permission of GlaxoSmithKline

Product Specifications for SB 525334

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SB 525334

The following data is based on the product molecular weight 343.42.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

5 4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.91 mL	14.56 mL	29.12 mL
5 mM	0.58 mL	2.91 mL	5.82 mL
10 mM	0.29 mL	1.46 mL	2.91 mL
50 mM	0.06 mL	0.29 mL	0.58 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 44 publications citing the usage of this product.

• Higashiyama Inhibition of AVNreceptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis Exp.Mol.Pathol. 2007 PMID: 17274978
• Laping Tumor-specific efficacy of transforming growth factor-βRI inhibition in eker rats. Clin.Cancer Res. 2007 PMID: 17505012
• Grygielko Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-β type I receptor kinase in puromycin-induced nephritis. J.Pharmacol.Exp.Ther. 2005 PMID: 15769863

Product Documents for SB 525334